Cambios en la densidad de masa ósea en mujeres con cáncer de mama precoz que han recibido quimioterapia adyuvante con y sin bifosfonatos

  1. Beatriz Alonso Álvarez
  2. María Remedios Alemán Valls
  3. Milva Rodríguez Rodríguez
  4. Marta Llanos Muñoz
  5. Carlos Emilio González Reimers
  6. N. Batista López
Revista:
Estudios Canarios: Anuario del Instituto de Estudios Canarios

ISSN: 0423-4804

Año de publicación: 2008

Número: 52

Páginas: 137-148

Tipo: Artículo

Resumen

Adjuvant therapies have prolonged survival of non-metastatic breast cancer (NMBC) patients, but they also decrease bone mineral density (BMD). There is increased interest in the potencial role of bisphosphonate drugs in preventing and treating chemotherapy-induced bone loss. We have analyzed the effects of chemotherapy on BMD of women with NMBC who received before first cycle intravenous zoledronic acid. We prospectively included 88 women with NMBC (stage I-III) referred to the Medica! Oncology Service of University Hospital of Canary Islands. We measured lumbar and hip BMD at diagnosis, and after chemotherapy. BMD after chemotherapy significantly increased trochanter and femoral neck areas, and remained stable lumbar, total hip, intertrochanter, and Ward' s triangle areas. Intravenous bisphosphonate (zoledronic acid) in our study have demostrate a benefit in reducing the loss bone mineral density after chemotherapy in women with NMBC